AVR engaged the FDA to progress the IDE for the PARADIGM Trial, with Michael J. Reardon confirmed as Co-Chair.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AVR engaged the FDA to progress the IDE for the PARADIGM Trial, with Michael J. Reardon confirmed as Co-Chair.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA approval enables commercial opportunity involving CBRE Group.
- Matricelf Ltd. is seeking feedback from the FDA regarding its clinical trial design. The company is currently listed on the Tel Aviv Stock Exchange with plans for a dual listing to support its transition.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA approval supports commercial partner contracts for Vericel.
Coverage
Newest first; wire copies grouped- GlobeNewswireAnteris Announces Results for the Second Quarter of 2025 MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR